
Opinion|Videos|May 7, 2024
Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD
Author(s)Marion R. Munk, MD, PhD
Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
The Retina TL;DR with Dr. Weng: Navigating the ocular risks of facial fillers with Jennifer Murdock, MD
2
Retina World Congress 2026: Can vibration reduce pain during intravitreal injections?
3
Retina World Congress 2026: Sunir J. Garg, MD, FACS, on preventing occupational injury in retina practice
4
Retina World Congress 2026: Diagnosing macular telangiectasia in a field of mimickers
5






















